JNJ

Johnson & Johnson

Add to Watchlist

Advanced Chart

174.210

-1.98(-1.124%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

176.640

Open

176.090

VWAP

174.55

Vol

7.19M

Mkt Cap

419.56B

Low

174.120

Amount

1.26B

EV/EBITDA(TTM)

14.74

Total Shares

2.41B

456.21B

EV/OCF(TTM)

19.81

P/S(TTM)

4.71

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

22.94B

+4.8%

2.690

-2.87%

24.05B

+6.78%

2.566

+25.79%

23.73B

+5.58%

2.750

+13.62%

Estimates Revision

The market is revising Upward the revenue expectations for Johnson & Johnson (JNJ) for FY2025, with the revenue forecasts being adjusted by 2.28% over the past three months. During the same period, the stock price has changed by 15.13%.

Revenue Estimates for FY2025

Revise Upward

+2.28%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.29%

In Past 3 Month

Stock Price

Go Up

+15.13%

In Past 3 Month

17 Analyst Rating

3.82% Upside

Wall Street analysts forecast JNJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 180.87 USD with a low forecast of 165.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

9 Hold

0 Sell

Moderate Buy

3.82% Upside

Current: 174.210

Low

165.00

Averages

180.87

High

200.00

3.82% Upside

Current: 174.210

Low

165.00

Averages

180.87

High

200.00

JPMorgan

Neutral

maintain

$185 -> $200

2025-09-16

Reason

JPMorgan

Price Target

$185 -> $200

2025-09-16

maintain

Neutral

Reason

JPMorgan raised the firm's price target on Johnson & Johnson to $200 from $185 and keeps a Neutral rating on the shares. The firm left its large cap biopharma estimates largely unchanged but adjusted price targets on a move to December 2026 from December 2025.

JPMorgan

Neutral

maintain

$185 -> $195

2025-09-16

Reason

JPMorgan

Price Target

$185 -> $195

2025-09-16

maintain

Neutral

Reason

JPMorgan raised the firm's price target on Johnson & Johnson to $195 from $185 and keeps a Neutral rating on the shares. The firm left its large cap biopharma estimates largely unchanged but adjusted price targets on a move to December 2026 from December 2025.

Leerink

Faisal A. Khurshid

Outperform

initiated

$73

2025-09-12

Reason

Leerink

Faisal A. Khurshid

Price Target

$73

2025-09-12

initiated

Outperform

Reason

Leerink analyst Faisal A. Khurshid initiated coverage of Protagonist Therapeutics (PTGX) with an Outperform rating and $73 price target. The firm points out that Protagonist's peptide drug discovery platform has generated not one but two promising assets that are soon to be commercialized in large markets. Both are partnered, rusfertide with Takeda (TAK) and icotrokinra with Johnson & Johnson (JNJ), which gives reassurance on the commercial outlook and provides Protagonist with attractive royalty economics, the firm argues. Longer-term growth will be driven by emerging pipeline assets from the company's now-validated platform, along with management continuing their track record of prudent capital allocation and business development execution, Leerink adds.

Citi

Buy

upgrade

$185 -> $200

2025-08-21

Reason

Citi

Price Target

$185 -> $200

2025-08-21

upgrade

Buy

Reason

Citi raised the firm's price target on Johnson & Johnson to $200 from $185 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology space following the Q2 reports. Citi views the overall sector as healthy and opened "positive catalyst watches" on Edwards Lifesciences (EW) and Penumbra (PEN). The analyst also added iRhythm (IRTC) to its medtech top picks list, alongside Boston Scientific (BSX) and Edwards.

Erste Group

Hans Engel

Hold

Buy

upgrade

2025-07-23

Reason

Erste Group

Hans Engel

Price Target

2025-07-23

upgrade

Hold

Buy

Reason

Erste Group analyst Hans Engel upgraded Johnson & Johnson to Buy from Hold. The firm, which notes that J&J has a higher operating margin and return on equity than its competitors, expects the stock price to rise further in the medium term given the company's improved growth prospects.

Barclays

Matt Miksic

Equal Weight

maintain

$165 -> $176

2025-07-17

Reason

Barclays

Matt Miksic

Price Target

$165 -> $176

2025-07-17

maintain

Equal Weight

Reason

Barclays analyst Matt Miksic raised the firm's price target on Johnson & Johnson to $176 from $165 and keeps an Equal Weight rating on the shares following the Q2 report. The firm says the company's sales and earnings beat on execution and currency.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Johnson & Johnson (JNJ.N) is 16.16, compared to its 5-year average forward P/E of 16.14. For a more detailed relative valuation and DCF analysis to assess Johnson & Johnson 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

16.14

Current PE

16.16

Overvalued PE

17.33

Undervalued PE

14.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

12.93

Current EV/EBITDA

13.39

Overvalued EV/EBITDA

13.72

Undervalued EV/EBITDA

12.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

4.47

Current PS

4.44

Overvalued PS

4.80

Undervalued PS

4.15

Financials

Annual

Quarterly

FY2025Q2

YoY :

+5.77%

23.74B

Total Revenue

FY2025Q2

YoY :

-1.24%

7.02B

Operating Profit

FY2025Q2

YoY :

+18.16%

5.54B

Net Income after Tax

FY2025Q2

YoY :

+18.65%

2.29

EPS - Diluted

FY2025Q2

YoY :

-39.12%

2.84B

Free Cash Flow

FY2025Q2

YoY :

-2.12%

67.94

Gross Profit Margin - %

FY2025Q2

YoY :

-12.71%

20.47

FCF Margin - %

FY2025Q2

YoY :

+11.69%

23.32

Net Margin - %

FY2025Q2

YoY :

-41.33%

19.29

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

38.7M

USD

3-6

Months

0.0

USD

6-9

Months

3.2M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

147.2K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

679.6K

Volume

6-9

Months

557.5K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

957.0K

Volume

Months

6-9

2.4M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

72.5K

USD

3-6

Months

220.0K

USD

6-9

Months

207.0K

USD

0-12

Months

382.5K

USD

Bought

0-3

40.5K

USD

Months

3-6

113.0K

USD

Months

6-9

275.0K

USD

Months

0-12

80.0K

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

38.7M

USD

3-6

Months

0.0

USD

6-9

Months

3.2M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

147.2K

USD

Months

JNJ News & Events

Events Timeline

2025-09-19 (ET)

2025-09-19

17:29:57

J&J announces FDA approval for Tremfya's SC induction regimen

2025-09-19

09:38:11

Johnson & Johnson Receives Favorable CHMP Opinion for Nipocalimab

2025-09-19

08:34:14

JNJ: TECVAYLI/DARZALEX FASPRO treatment demonstrates favorable outcomes in research

News

8.0

09-22WSJ

Essential Information on Using Tylenol While Pregnant

5.0

09-22Yahoo Finance

Johnson & Johnson (JNJ) Unveils Shockwave Javelin Peripheral IVL Catheter in Europe

2.0

09-22MarketWatch

Kenvue Claims Tylenol is Safe, Yet Stock Reaches All-Time Low Before Trump’s Speech

People Also Watch

Thermo Fisher Scientific Inc

UnitedHealth Group Inc

Costco Wholesale Corp

FAQ

What is Johnson & Johnson (JNJ) stock price today?

The current price of JNJ is 174.21 USD — it has decreased -1.12 % in the last trading day.

JNJ

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

JNJ News & Events

Events Timeline

News

People Also Watch

FAQ

What is Johnson & Johnson (JNJ) stock price today?

What is Johnson & Johnson (JNJ)'s business?

What is the price predicton of JNJ Stock?

What is Johnson & Johnson (JNJ)'s revenue for the last quarter?

What is Johnson & Johnson (JNJ)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Johnson & Johnson (JNJ)'s fundamentals?

How many employees does Johnson & Johnson (JNJ). have?

What is Johnson & Johnson (JNJ) market cap?